Biogen gears up for Alzheimer's drug launch

There are serious doubts about whether the FDA will approve Biogen’s Alzheimer’s candidate aducanumab – but is gearing up to file it with the regulator and is already looking ahead to a pot

2019: the year of the pharma mega-merger

2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year that changed the landscape of big pharma

FDA cues up May verdict for Roche’s SMA challenger risdiplam

Biogen bags FDA okay for Tecfidera follow-up Vumerity

Surprise! Biogen says Alzheimer’s drug works after all and w...

Humira tops list of drugs with unwarranted US price hikes